GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shijiazhuang Yiling Pharmaceutical Co Ltd (SZSE:002603) » Definitions » Gross-Profit-to-Asset %

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Gross-Profit-to-Asset % : 30.46% (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Shijiazhuang Yiling Pharmaceutical Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Shijiazhuang Yiling Pharmaceutical Co's annualized Gross Profit for the quarter that ended in Mar. 2024 was ¥5,194 Mil. Shijiazhuang Yiling Pharmaceutical Co's average Total Assets over the quarter that ended in Mar. 2024 was ¥17,054 Mil. Therefore, Shijiazhuang Yiling Pharmaceutical Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 30.46%.


Shijiazhuang Yiling Pharmaceutical Co Gross-Profit-to-Asset % Historical Data

The historical data trend for Shijiazhuang Yiling Pharmaceutical Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shijiazhuang Yiling Pharmaceutical Co Gross-Profit-to-Asset % Chart

Shijiazhuang Yiling Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.20 55.05 52.72 54.66 35.48

Shijiazhuang Yiling Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.13 35.95 23.37 15.78 30.46

Competitive Comparison of Shijiazhuang Yiling Pharmaceutical Co's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Shijiazhuang Yiling Pharmaceutical Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shijiazhuang Yiling Pharmaceutical Co's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shijiazhuang Yiling Pharmaceutical Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Shijiazhuang Yiling Pharmaceutical Co's Gross-Profit-to-Asset % falls into.



Shijiazhuang Yiling Pharmaceutical Co Gross-Profit-to-Asset % Calculation

Shijiazhuang Yiling Pharmaceutical Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=5910.504/( (16340.66+16979.327)/ 2 )
=5910.504/16659.9935
=35.48 %

Shijiazhuang Yiling Pharmaceutical Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=5194.288/( (16979.327+17128.471)/ 2 )
=5194.288/17053.899
=30.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Shijiazhuang Yiling Pharmaceutical Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Shijiazhuang Yiling Pharmaceutical Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Business Description

Traded in Other Exchanges
N/A
Address
No. 7 Tianfu street, Biology and medicine industrial base, Huangcun town, Daxing district, Beijing, CHN
Shijiazhuang Yiling Pharmaceutical Co Ltd is a China-based company engages in the pharmaceutical manufacturing. The company is principally engaged in the research, development, manufacturing, and sales of traditional Chinese pharmaceutical products, especially in the fields of cardiovascular and cerebrovascular diseases, respiratory diseases, tumor, diabetes and related complications. Its products include innovative drug series, chemical drugs, Chinese medicine series, and health products.
Executives
Zhang Qiu Lian Directors, executives
Han Yue Zhi Executives
Zhao Shao Hua Executives
Wang Wei Executives
Gao Xue Dong Supervisors
Wu Yi Ling Director
Gao Xiu Qiang Executives
Wu Xiang Jun Directors, executives
Guo Shuang Geng Director
Wang Hua Securities Affairs Representative
Dai Feng Xiang Directors, executives
Liu Gen Wu Supervisors
Wang Wei Ping Directors, executives
Xu Wei Dong Director
Wu Rui Directors, executives

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Headlines

No Headlines